Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Condition(s) targeted: Secondary Peritonitis; Abscess, Intra-Abdominal

Intervention: Moxifloxacin (Avelox, BAY12-8039) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

This study is a local, prospective, open-label, company-sponsored, non interventional, multi-center study. Patients documented must suffer from a cIAI and take at least one dose of Moxifloxacin infusion. The primary objective is to define the types of cIAI infections that require Moxifloxacin i. v. therapy in China.

Official title: Clinical Effectiveness and Safety Study of Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Types of cIAI infections

Secondary outcome:

Cure rate

Clinical signs and symptoms

Duration until improvement and cure

Adverse event collection

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients at least 18 years of age with a diagnosis of cIAI treated with Moxifloxacin

infusion with/without sequential tablet treatment can be included into the study. The local Moxifloxacin product information must be considered. Exclusion Criteria:

- Contraindications stated in the local Moxifloxacin product information. Warnings and

precautions, stated in the local Moxifloxacin product information must be considered as potential exclusion criteria.

Many locations, China

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: December 2009
Last updated: June 20, 2013